D. Boral Capital Reiterates Buy Rating for UroGen Pharma (NASDAQ:URGN)

UroGen Pharma (NASDAQ:URGN)‘s stock had its “buy” rating reissued by equities research analysts at D. Boral Capital in a note issued to investors on Wednesday,Benzinga reports. They currently have a $25.00 target price on the stock. D. Boral Capital’s target price points to a potential upside of 137.64% from the stock’s current price.

Other equities research analysts have also recently issued research reports about the stock. HC Wainwright restated a “buy” rating and issued a $60.00 price objective on shares of UroGen Pharma in a report on Tuesday, October 15th. Oppenheimer restated an “outperform” rating and issued a $40.00 price target on shares of UroGen Pharma in a research note on Wednesday, October 16th. Finally, EF Hutton Acquisition Co. I raised UroGen Pharma to a “strong-buy” rating in a research report on Monday, October 14th. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $43.70.

UroGen Pharma Trading Up 1.3 %

NASDAQ URGN opened at $10.52 on Wednesday. The firm has a market capitalization of $246.74 million, a PE ratio of -3.34 and a beta of 1.09. The stock’s 50 day moving average is $11.46 and its 200 day moving average is $13.19. UroGen Pharma has a twelve month low of $9.78 and a twelve month high of $20.70. The company has a quick ratio of 8.77, a current ratio of 9.00 and a debt-to-equity ratio of 4.77.

UroGen Pharma (NASDAQ:URGN) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.55) EPS for the quarter, beating the consensus estimate of ($0.84) by $0.29. The firm had revenue of $25.20 million for the quarter, compared to analysts’ expectations of $24.22 million. During the same period in the prior year, the business posted ($0.68) EPS. Research analysts forecast that UroGen Pharma will post -3.1 earnings per share for the current fiscal year.

Institutional Investors Weigh In On UroGen Pharma

A number of institutional investors have recently made changes to their positions in the company. Marshall Wace LLP bought a new position in UroGen Pharma in the 2nd quarter valued at approximately $719,000. Millennium Management LLC raised its stake in shares of UroGen Pharma by 2,672.0% in the second quarter. Millennium Management LLC now owns 1,160,899 shares of the company’s stock worth $19,480,000 after purchasing an additional 1,119,019 shares during the last quarter. Barclays PLC lifted its holdings in shares of UroGen Pharma by 409.3% during the third quarter. Barclays PLC now owns 59,778 shares of the company’s stock valued at $759,000 after purchasing an additional 48,040 shares in the last quarter. Point72 Asset Management L.P. boosted its position in shares of UroGen Pharma by 120.3% during the second quarter. Point72 Asset Management L.P. now owns 2,449,277 shares of the company’s stock valued at $41,099,000 after buying an additional 1,337,257 shares during the last quarter. Finally, Wesbanco Bank Inc. purchased a new stake in shares of UroGen Pharma during the third quarter valued at $945,000. Hedge funds and other institutional investors own 91.29% of the company’s stock.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.